Overview

Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Status:
NOT_YET_RECRUITING
Trial end date:
2030-03-01
Target enrollment:
Participant gender:
Summary
Based on the efficacy of tarlatamab in patients with small-cell lung cancer, we aim to assess the efficacy of tarlatamab in patients with Advanced, pulmonary (large-cell only) or gastroenteropancreatic neuroendocrine carcinoma.
Phase:
PHASE3
Details
Lead Sponsor:
Intergroupe Francophone de Cancerologie Thoracique